Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01TDV
|
||||
Former ID |
DIB019176
|
||||
Drug Name |
compound 1
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1], [2] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C25H28N6O2
|
||||
InChI |
InChI=1S/C25H28N6O2/c1-29-12-14-30(15-13-29)22-10-5-19(16-23(22)33-3)27-24-11-4-18-17-26-31(25(18)28-24)20-6-8-21(32-2)9-7-20/h4-11,16-17H,12-15H2,1-3H3,(H,27,28)
|
||||
InChIKey |
LZQFMCFJCXQTTG-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | mRNA of Aurora B | Target Info | Inhibitor | [2] | |
STK33 | Target Info | Inhibitor | [1] | ||
Protein kinase A | Target Info | Inhibitor | [2] | ||
Pathway Interaction Database | Aurora B signaling | ||||
Signaling by Aurora kinases | |||||
Aurora C signaling | |||||
FOXM1 transcription factor network | |||||
Aurora A signaling | |||||
Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
Separation of Sister Chromatids | |||||
Resolution of Sister Chromatid Cohesion | |||||
RHO GTPases Activate Formins | |||||
Mitotic Prometaphase | |||||
WikiPathways | Mitotic Metaphase and Anaphase | ||||
Mitotic Prometaphase | |||||
Regulation of Microtubule Cytoskeleton | |||||
miR-targeted genes in lymphocytes - TarBase | |||||
miR-targeted genes in epithelium - TarBase | |||||
APC/C-mediated degradation of cell cycle proteins | |||||
References | |||||
REF 1 | STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011 Sep 1;71(17):5818-26. | ||||
REF 2 | A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038. Epub 2012 Oct 22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.